Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 52,744 | 53,399 | 65,494 | 47,638 | 38,350 |
| Cost of Goods | 26,993 | 24,319 | 22,982 | 19,592 | 16,349 |
| Gross Profit | 25,751 | 29,080 | 42,512 | 28,046 | 22,001 |
| Operating Expenses | 32,244 | 25,482 | 33,034 | 41,652 | 42,812 |
| Operating Income | -5,500 | 3,917 | 10,460 | -13,014 | -20,462 |
| Other Income | -108 | 237 | -1,894 | -1,383 | -7,120 |
| Pre-tax Income | -5,608 | 4,154 | 8,566 | -14,397 | -27,582 |
| Income Tax | 996 | 1,222 | 254 | 530 | N/A |
| Net Income Continuous | -6,604 | 2,932 | 8,312 | -14,927 | -27,582 |
| Net Income | $-6,604 | $2,932 | $8,312 | $-14,927 | $-27,582 |
| EPS Basic Total Ops | -0.08 | 0.04 | 0.12 | -0.31 | -0.62 |
| EPS Basic Continuous Ops | -0.08 | 0.04 | 0.12 | -0.31 | -0.62 |
| EPS Diluted Total Ops | -0.08 | 0.04 | 0.09 | -0.31 | -0.62 |
| EPS Diluted Continuous Ops | -0.08 | 0.04 | 0.10 | -0.31 | -0.62 |
| EPS Diluted Before Non-Recurring Items | N/A | 0.04 | 0.09 | -0.31 | -0.62 |
| EBITDA(a) | $-4,035 | $5,221 | $11,918 | $-11,628 | $-16,671 |